NEW YORK (GenomeWeb News) — Genomic Health today said that Aetna has set payment rates for its Oncotype DX test for early-stage breast cancer patients.
Genomic Health said Aetna, which  began covering the test in August, has set rates for all of its plans for breast cancer patients for the test, which quantifies the odds of breast cancer recurrence and predicts the chances of the effectiveness of chemotherapy treatment.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.